Navigation Links
Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
Date:2/19/2008

a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll 's lead product, Gentamicin Surgical Implant for the treatment and prevention of surgical site infections, is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia and is marketed under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R), and CRONOCOL(R). In 2005, Innocoll acquired the worldwide marketing rights for this product from Essex Chemis AG, an affiliated company of Schering-Plough Corporation (NYSE: SGP) and in August 2007 sold its marketing rights, with the exception of the US, to EUSA Pharma. Gentamicin Surgical Implant is currently in phase 3 development in the US for the prevention of surgical site infections. Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers and CollaRx Bupivacaine Implant for the management of post-operative pain, both of which are currently in Phase 2 development. For more information, please visit http://www.innocollinc.com.


'/>"/>
SOURCE Innocoll, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
5. Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
6. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
7. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
10. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
11. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 ... has announced the addition of the  "2015 ... Market"  report to their offering.  ... comprehensive five-country report contains 500 pages, 120 ... suppliers and potential market entrants identify and ...
(Date:5/27/2015)... , May 27, 2015 Protein purification ... based on differences in their physical properties. The objective ... largest amount of functional protein with fewest contaminants. The ... grow at a CAGR of around 5% to 6% ... by increased research in the pharmaceutical and biotechnological fields, ...
(Date:5/27/2015)... DUBLIN , May 27, 2015 /PRNewswire/ ... ) has announced the addition of the  ... Trends And Forecasts (2014 - 2019)" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,Ultrasound is ... sound waves to look at body parts ...
Breaking Medicine Technology:European Hemostasis Diagnostic Testing Market Strategies 2015 2Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 2Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 3Asia Pacific Ultrasound Devices Market Report 2015 - Growth, Trends And Forecasts 2014 - 2019 2
... ANNAPOLIS, Md., April 13, 2011 PharmAthene, Inc. (NYSE ... has completed dosing in a U.S. Phase I clinical ... being developed for the prevention and treatment of inhalational ... clinical trial was designed to evaluate single escalating doses ...
... HONOLULU, April 13, 2011 Today, GE Healthcare announced ... the impact of DaTscan™ SPECT imaging on the clinical ... or symptoms of parkinsonian syndromes (PS). The results, presented ... an important step in documenting the value of DaTscan ...
Cached Medicine Technology:PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial 2PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial 3GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 2GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 3GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 4GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 5GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 6
(Date:5/27/2015)... 27, 2015 The BBB Code of ... practices that enhance customer trust and confidence in business. ... Trust, eight principles that summarize important elements of creating ... standards for business accreditation by BBB. Businesses based in ... and complete application procedures will be accredited by BBB. ...
(Date:5/27/2015)... May 27, 2015 With the launch ... more robust Network Management Module (NMM) tool, monitoring provider-network ... 21 issue of Atlantic Information Services, Inc.’s (AIS) Medicare ... NMM tool, as well as analysis from industry experts ... The changes coming to the NMM were announced at ...
(Date:5/27/2015)... Austin, TX (PRWEB) May 27, 2015 ... gas information. Topics include: Why investors should consider oil ... investors, how and why wells are drilled, industry news, ... , Carson Energy's 32 years of knowledge and experience ... and gas investment community to be able to access ...
(Date:5/27/2015)... May 27, 2015 The Case ... a partnership to provide CMSA's Career and Knowledge ... collaboration seeks to strengthen the case/care management workforce ... CKP program. The mutually beneficial agreement provides Medix, ... skills of talent in the healthcare, scientific and ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Coco Libre announced ... be able to reach for Organic Coconut Water to quench ... will be available at VIP areas, artist greenrooms, corporate skyboxes ... available at area hotels and on festival shuttle buses. ... this year,” said Noa Elan, Director of Strategic Partnerships for ...
Breaking Medicine News(10 mins):Health News:Carson Energy Receives A+ Accredited Rating For 19 Consecutive Years 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Coco Libre Puts Organic Coconut Water on the Line-up at BottleRock Napa 2
... New Zealand Aids Foundation has welcomed a decision by Pharmac(the ... the same time, they say delays over the funding may ... medicines, to be subsidized from April 1, 2007 are Tenofovir ... to Pharmac’s medical director Dr Peter Moodie the investment would ...
... slower in children who wear a special kind of ... lenses// according to a new study published in Investigative ... found that among children with two myopic parents, myopia ... when compared to those wearing single-vision lenses (SVLs).Knowing parental ...
... by a specialist headache centre, it was observed that eight ... at work; 91 per cent blamed the ineffectiveness to headaches, ... published in the March issue of Cephalalgia. ,"Migraines ... when they are often at their most productive, so the ...
... suggests that genes responsible for generating matrix metalloproteinase 1 ... long term hip replacement surgery. ,The researchers ... of whom (162) had problems after hip replacement in ... with symptoms, 91 had early signs of 'aseptic loosening,' ...
... SAN DIEGO--(BUSINESS WIRE)--Ichor Medical Systems, whose advanced electroporation ... effectiveness// of DNA drug and vaccine delivery, has ... $900,000 by the United States Department of Defense ... Institute of Infectious Diseases (USAMRIID) in Fort Detrick, ...
... certainly be an indicator of one’s happiness. Researchers at the ... nation's overall happiness and its citizens' blood pressure problems. ... across the European countries. ,These people were asked how happy ... blood pressure) and so on. ,While Sweden, Denmark ...
Cached Medicine News:Health News:New Zealand’s Pharmac Subsidies Two More HIV Drug 2Health News:Work Absence Due to Headaches Has a Substantial Socio-economic Effect 2Health News:United States Department of Defense Selects Ichor Medical Systems to Develop Biodefense Vaccine 2
Midstream Catch Kits...
... a portable, noninvasive ultrasound instrument that measures ... use, and quickly provides accurate results. In ... the BladderScan® to obtain a precise reading ... supplies the information that caregivers need to ...
... The BladderScan® BVI 6100 is a handheld, ... It is easy to operate, so any ... accurately. To view ultrasound images from exams ... patient records and reimbursement, just log on ...
... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
Medicine Products: